# Lecture 10: NSAIDs & Acetaminophen

## Arachidonic Acid Pathway

Arachidonic acid → 2 pathways:
1. **Lipoxygenase** → Leukotrienes
2. **Cyclooxygenase (COX)** → Prostaglandins, Thromboxane, Prostacyclin

### COX Products

| Product | Function |
|---------|----------|
| **PGE2** | Pain sensitization, fever, GI protection, renal vasodilation |
| **PGI2 (Prostacyclin)** | Vasodilation, inhibits platelet aggregation, GI/renal protection |
| **TXA2 (Thromboxane)** | Vasoconstriction, promotes platelet aggregation |

---

## COX-1 vs COX-2

| Feature | COX-1 | COX-2 |
|---------|-------|-------|
| Expression | **Ubiquitous** (constitutive) | Inducible at inflammation sites |
| Function | GI mucosa maintenance, platelet function | Inflammation, pain, fever |
| Renal | - | Maintains renal blood flow in low-volume states |

---

## NSAID Effects by System

| System | Effect | Mechanism |
|--------|--------|-----------|
| **Pain** | Anti-nociceptive | PGE2/PGI2 normally sensitize peripheral nerve endings |
| **Inflammation** | Decrease swelling | PGE2/PGI2 cause vascular permeability and leukocyte infiltration |
| **Fever** | Antipyretic | PGE2 signals hypothalamus to raise temperature set point |
| **GI** | Ulcers, bleeding | COX-1 maintains GI mucosa |
| **Kidney** | AKI, salt/water retention | PGE/PGI maintain renal blood flow via vasodilation |
| **CV** | Disrupts platelet homeostasis | Affects balance of TXA2 and PGI2 |

---

## Key NSAIDs

| Drug | Selectivity | Key Points |
|------|-------------|------------|
| **Aspirin** | Non-selective | **Irreversibly** acetylates COX-1 in platelets; used for CAD, not pain |
| **Indomethacin** | Non-selective | Potent |
| **Naproxen** | Non-selective | Longer half-life (slower onset) |
| **Nabumetone** | Non-selective | Half-life < 24 hours |
| **Diclofenac** | More COX-2 | Less GI effects, accumulates in synovial fluid (good for arthritis) |
| **Ketorolac** | More COX-2 | Less GI effects, high risk of renal failure with long-term use |
| **Celecoxib** | **COX-2 selective** | Minimizes GI/bleeding; also inhibits CYP2D6 |

---

## Aspirin

### Unique Properties
- **Irreversibly acetylates** COX-1 in platelets
- Primary use: **Coronary artery disease** (antiplatelet), not pain

### Aspirin Overdose
**Symptoms**: Tinnitus, fast breathing, nausea, GI pain, fever

**Stages**:
1. Respiratory alkalosis
2. Compensatory metabolic acidosis
3. Interference with oxidative phosphorylation
4. Fever and worsening metabolic acidosis

**Treatment**: IV sodium bicarbonate (alkalinizes urine to trap aspirin)

### Special Conditions
| Condition | Details |
|-----------|---------|
| **Reye Syndrome** | Aspirin + varicella/influenza in children → severe hepatic injury + encephalopathy |
| **AERD (Samter's Triad)** | Nasal polyps + Asthma + Aspirin sensitivity |

### AERD Mechanism
- Increased PGD2 (COX-2) = bronchoconstrictor
- Decreased PGE2 (COX-1) = bronchodilator
- Shift toward leukotrienes → bronchoconstriction

---

## COX-2 Selective Inhibitors

### Why Initially Considered Superior?
- Minimizes GI and bleeding side effects

### Why Some Removed from Market?
- Significant increases in **cardiovascular/neurovascular events**
- PGI2 has protective effect in atherogenic process
- COX-2 inhibition creates imbalance → promotes vasoconstriction and platelet aggregation

**Caution**: Use cautiously in patients with CV risk factors and uncontrolled HTN

---

## Prostaglandin Analogs

| Drug | Type | Use |
|------|------|-----|
| **Misoprostol** | PGE1 derivative | Peptic ulcer prophylaxis, labor induction, early pregnancy termination |
| **Alprostadil** | PGE1 synthetic | Erectile dysfunction (muscle relaxer) |
| **Epoprostenol** | PGI2 analog | Pulmonary hypertension |

---

## NSAID Co-Administration

| Drug | Purpose |
|------|---------|
| **PPIs** | Prophylaxis for peptic ulcer disease |
| **Misoprostol** | GI protection |

---

## Acetaminophen (Paracetamol)

### Key Facts
- Generic: **Para-acetyl-aminophenol (paracetamol)**
- NOT an NSAID (no anti-inflammatory effect)
- Mechanism not fully understood

### Toxicity
| Parameter | Details |
|-----------|---------|
| **Toxic dose** | > 7.5 grams |
| **Primary concern** | Hepatotoxicity |
| **Toxic metabolite** | NAPQI (N-acetyl-p-benzoquinoneimine) |
| **Detoxification** | Glutathione conjugation |

### Treatment of Overdose
1. **Activated charcoal** - decreases absorption
2. **N-acetylcysteine (NAC)** - glutathione precursor, replenishes stores
